EAA181

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jul 27, 2022 → Oct 15, 2026

Cited window

Jul 27, 2022 → Oct 15, 2026

Retrieved

Oct 18, 2026

Title

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Registry

NCT04566328

Study IDs

EAA181 · NCI-2020-06647 (CTRP (Clinical Trial Reporting Program)) · U10CA180820

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

National Cancer Institute (NCI)

Design

Phase 3 · Interventional, randomized, sequential

Status

Recruiting

Enrollment

1,450 estimated

Start

2021-02-24 actual

Primary completion

2027-12-31 estimated

Primary endpoint

Consolidation overall survival

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –105 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits apply, so some matching discussion may be missing.
• –The sources reviewed for this edition are not a representative sample of all HCP opinion. Repeated posts from one author do not establish consensus or prescribing uptake.
• –Many recording passages cannot be assigned confidently to a named individual. Their views are reported anonymously rather than inferred from a program, participant list or professional profile.
• –No exact-trial publication or standalone protocol was available. Study descriptions in commentary must therefore remain speakers' accounts, and other-trial results must not be read as EQUATE outcomes.
• –Some social-media conversations and one podcast were unavailable. Other passages in included recordings were not fully assessed, including parts of the discussion of early MRD-guided transplant omission, slow response and sustained negativity.
• –The reported direction of BENEFIT's MRD comparison differs between Derman's post and the later podcast account. Both are preserved as source-specific statements rather than reconciled into a single result.
• –Several numerical comparisons are approximate recollections or cross-trial observations. Censoring explanations, exposure interpretations and proposed reasons for age limits are hypotheses, not demonstrated analyses in this edition.
• –Future stopping strategies, blood-monitoring algorithms, genetic prediction tools and earlier immune-therapy sequences remain conditional or investigational in the statements cited.
• –The supplied registry description of the treatment comparison is abbreviated. The report does not reconstruct missing regimen details or infer current recruitment from an announcement's activation date.

How reports are built and checked: Methods.

Last checked for new commentary Oct 18, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.